TGFB1 and systemic sclerosis: The antifibrotic effect of nintedanib was recently tested in cultured MDMs obtained from SSc-ILD patients; these cells were characterized by a profibrotic M2 phenotype with a significantly high expression of cell membrane (CD204, CD206 and CD163) and functional markers of profibrotic M2 phenotype (MerTK and TGFβ1) compared to cultured MDMs obtained from HSs and SSc patients without ILD (47).